Iguana Healthcare Management LLC grew its position in shares of Celgene Corporation (NASDAQ:CELG) by 12.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,000 shares of the biopharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Celgene Corporation comprises 5.5% of Iguana Healthcare Management LLC’s holdings, making the stock its 2nd largest holding. Iguana Healthcare Management LLC’s holdings in Celgene Corporation were worth $11,199,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Motco boosted its position in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Celgene Corporation during the 1st quarter valued at $118,000. Oakworth Capital Inc. lifted its position in shares of Celgene Corporation by 60.9% during the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the last quarter. Finally, Nicolet Bankshares Inc. purchased a new position in shares of Celgene Corporation during the 1st quarter valued at $187,000. Hedge funds and other institutional investors own 79.43% of the company’s stock.

In related news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the sale, the director now owns 9,250 shares in the company, valued at approximately $1,286,027.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Friedman sold 10,000 shares of Celgene Corporation stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $132.50, for a total transaction of $1,325,000.00. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at approximately $662,500. The disclosure for this sale can be found here. Insiders sold a total of 263,011 shares of company stock valued at $35,078,473 in the last quarter. 0.95% of the stock is owned by insiders.

A number of research firms recently issued reports on CELG. Vetr lowered Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 price objective on the stock. in a research note on Wednesday. BTIG Research restated a “neutral” rating on shares of Celgene Corporation in a research note on Tuesday, September 5th. Mizuho set a $134.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $147.31.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Stake Raised by Iguana Healthcare Management LLC” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/10/celgene-corporation-celg-stake-raised-by-iguana-healthcare-management-llc.html.

Shares of Celgene Corporation (CELG) traded down 0.89% during mid-day trading on Friday, hitting $140.50. The company had a trading volume of 3,675,872 shares. The firm has a market capitalization of $109.92 billion, a price-to-earnings ratio of 43.51 and a beta of 1.89. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.64. The firm has a 50-day moving average price of $134.31 and a 200 day moving average price of $126.68.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the firm earned $1.44 EPS. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.